valsartan has been researched along with Bright Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, L; Jin, H; Wang, D; Wang, Y; Wei, L; Zhang, L; Zhang, X | 1 |
| Aritomi, S; Koganei, H; Konda, T; Mitsui, A; Nitta, K; Ogawa, T; Wagatsuma, H | 1 |
| Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T | 1 |
| Border, WA; Cheung, AK; Gu, C; Huang, Y; Noble, NA; Zhou, G | 1 |
| Akashiba, A; Ando, N; Inada, H; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Ohta, S; Ono, H; Takahashi, T; Tsukada, K; Yoshii, M | 1 |
| Khan, F; Kumagai, N; Mahmood, J; Morioka, T; Oite, T; Okada, S | 1 |
| Chen, WD; Huang, YY; Li, LH; Wang, YW; Xu, HH; Yang, LC; Yang, YL; Zhang, DY; Zhu, XJ | 1 |
| Kolina, IB; Neverov, NI; Shilov, EM; Shvetsov, MIu; Stavrovskaia, EV; Zakharova, EV | 1 |
| Kozlovskaia, NL; Medvedeva, TIu; Miroshnichenko, NG; Okonova, EB; Plieva, OK; Rudenko, TE; Shonichev, DG; Shvetsov, MIu; Stavrovskaia, EV | 1 |
2 trial(s) available for valsartan and Bright Disease
| Article | Year |
|---|---|
Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Female; Glomerulonephritis; Humans; Middle Aged; Nephrosclerosis; Proteinuria; Renal Insufficiency, Chronic; Tetrazoles; Valine; Valsartan | 2005 |
[Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Follow-Up Studies; Glomerulonephritis; Humans; Hypertension; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
7 other study(ies) available for valsartan and Bright Disease
| Article | Year |
|---|---|
[Shendi granules regulates the balance of T cell subsets and down-regulates podocalyxin in rats with mesangial proliferative glomerulonephritis].
Topics: Animals; B7-1 Antigen; Calcineurin; Cytokines; Down-Regulation; Drugs, Chinese Herbal; Glomerulonephritis; Male; Rats; Rats, Sprague-Dawley; Sialoglycoproteins; T-Lymphocyte Subsets; Valsartan | 2017 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Glomerulonephritis; Hypertension; Kidney; Kidney Diseases; Male; Organ Size; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dihydropyridines; Disease Progression; Drug Therapy, Combination; Glomerulonephritis; Glucagon; Glucose Transporter Type 1; Glycated Hemoglobin; Glycogen; Hypertension; Kidney; Male; Norepinephrine; Proteinuria; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2013 |
Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Fibrosis; Glomerulonephritis; Intracellular Signaling Peptides and Proteins; Kidney; Kidney Function Tests; Male; Membrane Proteins; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2014 |
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Progression; Drug Implants; Female; Gene Expression Regulation; Glomerulonephritis; Isoantibodies; Kidney Glomerulus; Microcirculation; Nephrectomy; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 2006 |
[Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Chronic Disease; Drug Therapy, Combination; Female; Glomerulonephritis; Humans; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan; Young Adult | 2007 |
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anticholesteremic Agents; Antihypertensive Agents; Azathioprine; Captopril; Cholesterol; Creatinine; Cyclophosphamide; Data Interpretation, Statistical; Enalapril; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Lovastatin; Male; Nephrotic Syndrome; Prednisolone; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |